Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices

By LabMedica International staff writers
Posted on 18 Aug 2026

Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. More...

These limitations can slow diagnosis and restrict use at the bedside or in resource-limited settings. Although phase-based methods can reveal important morphological details, conventional systems often trade accuracy for speed and compactness. Researchers have now developed an ultrathin metasurface approach designed to capture quantitative phase information on smaller sensors, supporting more compact clinical imaging devices.

Researchers at the Australian Research Council Centre of Excellence for Transformative Meta-Optical Systems (TMOS), working across RMIT University and The University of Melbourne, have created a metasurface that supports quantitative phase microscopy (QPM). The device images microscopic objects that are nearly invisible to conventional intensity-based optics. It is designed to enable compact, field-deployable imaging for clinical and research settings.

The metasurface is “nonlocal,” meaning it processes the entire image rather than redirecting individual rays like a lens. Because it can sit directly in front of the sample, it reduces space and alignment demands. It integrates multiple nanostructured elements onto a single ultrathin surface to deliver phase-contrast information with minimal hardware movement.

Quantitative phase microscopy (QPM) requires phase-gradient measurements along two perpendicular directions. Conventional approaches typically obtain these measurements by rotating optical elements or swapping components, adding time and complexity to the imaging workflow. The new design integrates two sets of wavelength-selective nanostructures onto a single surface, allowing users to switch between orthogonal measurements simply by changing the illumination wavelength. The researchers also incorporated differential phase contrast to reduce noise and improve reconstructed phase maps.

Published in Nanophotonics on July 1, 2026, the approach is intended to simplify imaging workflows for conditions in which cell shape and growth patterns are clinically relevant, including sickle cell disease, cancer, and neurodegenerative disorders. The researchers note that near-term challenges include the cost of supporting hardware and fabrication, as well as the need for precisely tuned dual-wavelength illumination. They are also exploring integration with commercial microscopes using an infrared light-emitting diode.

Related Links
TMOS


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.